ProQR Therapeutics' (PRQR) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• ProQR Therapeutics has received a "sell (D-)" rating from Weiss Ratings, reaffirming a negative outlook on the stock.
• The stock currently has a Moderate Buy** average rating** with a price target range from various analysts, including $4.00 and $8.00.
• In the latest earnings report, ProQR missed analysts' expectations with a loss of ($0.14) earnings per share compared to a consensus estimate of ($0.08).

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other brokerages also recently issued reports on PRQR. Cantor Fitzgerald reissued an "overweight" rating and issued a $8.00 price target on shares of ProQR Therapeutics in a report on Friday, June 27th. Chardan Capital reissued a "buy" rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Friday, August 8th. JMP Securities restated a "market outperform" rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research report on Friday, June 27th. Finally, Evercore ISI restated an "outperform" rating on shares of ProQR Therapeutics in a research report on Friday, July 11th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $8.00.

ProQR Therapeutics Trading Up 4.0%

Shares of ProQR Therapeutics stock opened at $2.36 on Wednesday. ProQR Therapeutics has a 12-month low of $1.07 and a 12-month high of $4.62. The company has a market cap of $248.30 million, a price-to-earnings ratio of -5.13 and a beta of 0.23. The company's 50-day moving average price is $2.17 and its 200-day moving average price is $1.90.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). ProQR Therapeutics had a negative return on equity of 61.25% and a negative net margin of 238.52%.The firm had revenue of $4.33 million during the quarter, compared to analysts' expectations of $5.01 million. On average, sell-side analysts predict that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PRQR. Osaic Holdings Inc. grew its position in ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 4,500 shares during the last quarter. Vontobel Holding Ltd. bought a new position in ProQR Therapeutics during the first quarter valued at approximately $48,000. OneDigital Investment Advisors LLC grew its holdings in shares of ProQR Therapeutics by 45.5% in the first quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 12,500 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in shares of ProQR Therapeutics in the first quarter worth approximately $64,000. Finally, Jane Street Group LLC grew its holdings in shares of ProQR Therapeutics by 699.3% in the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company's stock worth $121,000 after purchasing an additional 79,720 shares during the last quarter. 32.65% of the stock is currently owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.